Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Topigen Pharmaceuticals Inc.

Division of Pharmaxis Ltd.
www.topigen.com

Latest From Topigen Pharmaceuticals Inc.

Relmada Therapeutics Announces Promotions

Relmada Therapeutics, Inc. has promoted Richard M. Mangano to chief scientific officer and Lisa Nolan to the newly created role of chief business officer. Mangano has experience leading R&D programs and previously held positions in discovery and clinical research at Hoffmann-La Roche, Lederle Laboratories, Wyeth Research, where he was acting therapeutic area director for neuroscience; and Adolor Corp., where he was vice-president of clinical research and development. Previously, Nolan was chief business officer at Topigen Pharmaceuticals, prior to this she was vice-president of global business development and strategic marketing for Skyepharma PLC. Nolan also held various senior positions in business and marketing at West Pharmaceutical Services, Elan Corp., and Zeneca Pharmaceuticals. 

Companies

Advanced Cell Technology grabs Antares CEO

Regenerative medicine company Advanced Cell Technology (ACT) has appointed Paul Wotton CEO and president, six months after starting its search for a new leader. The firm's most recent chief, Gary Rabin, left the company in January for unspecified reasons and, since then, Edward Myles, CFO and executive vice-president of corporate development, has been interim president. Mr Rabin took the reins in December 2010 after the sudden death of previous CEO William Caldwell. New leader Dr Wotton joins from Antares Pharma, where he has served as president and CEO since October 2008; before this, he was CEO of Topigen Pharmaceuticals and previously was the global head of business development of SkyePharma. Dr Wotton says ACT is at a "pivotal time," about to go into Phase II clinical trials for age-related macular degeneration (AMD) and Stargardt's macular dystrophy (SMD), Phase I for myopic macular degeneration (MMD), and to "advance the novel programs in its pre-clinical pipeline."

NicOx axes half of French staff to extend cash runway

NicOx is to halve its workforce at its headquarters in France and is considering restructuring its research centre in Italy after another costly nine months, in which its net loss fell only slightly to €37.8 million from €39.9 million in the same period last year.

Dermatology Orthopedics

Pharmaxis completes Topigen acquisition as antifibrotic moves forward

Pharmaxis has completed its acquisition of the private Canadian firm Topigen Pharmaceuticals in a move which expands its development portfolio in the respiratory area.

Orthopedics Respiratory
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
      • Pulmonary
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Pharmaxis Ltd.
  • Senior Management
  • Mark Parry-Billings , PhD, CEO
    Robert Boisjoli, CFO
    Lisa Nolan, PhD, SVP, Bus. Dev.
  • Contact Info
  • Topigen Pharmaceuticals Inc.
    Phone: (514) 868-0077
    2901 Rachel St.
    Ste. 13
    Montreal, H1W 4A4
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register